

Title: *Plasmodium falciparum* multidrug resistance 1 gene polymorphisms associated with outcomes after antimalarial treatment

Running title: *Pfmdr1* and malaria outcomes

Veronika R. Laird^{1,2,3}, Mateusz M. Plucinski², Meera Venkatesan⁴, Kelsey A. Rondini^{2,5}, Milijaona Randrianarivelojosia^{6,7}, Mauricette N. Andriamananjara⁸, Hawela Moonga⁹, Deus S. Ishengoma¹⁰, Arlindo Chidimatembue¹¹, Pedro Rafael Dimbu¹², Adicatou-Lai Adeothy¹³, Abdoul Habib Beavogui¹⁴, Simon Kariuki¹⁵, Sam L. Nsoya¹⁶, Aline Uwimana¹⁷, Gauthier Mesia Kahunu^{18,19}, Ashenafi Assefa²⁰, Ousmane A. Koita²¹, Naomi W. Lucchi^{22,23}, Samaly S. Svigel Souza²³, Zhiyong Zhou²³, Leah F. Moriarty², Eric S. Halsey²

Article word count (Introduction through Discussion): 3,488

Corresponding author:

Veronika R. Laird
2006 E Lombard
Baltimore, MD
21231
USA

veronika.laird97@gmail.com

Alternate corresponding author:

Eric Halsey
1600 Clifton Road
Mail Stop: H16-4
Atlanta, GA 30329
USA

Affiliations:

¹Department of Epidemiology, Emory University, Atlanta, GA, USA.

²US President's Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA

³Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, United States

⁴US President's Malaria Initiative, United States Agency for International Development, Washington, DC, USA

⁵Booz Allen Hamilton, Atlanta, GA, USA

⁶Institut Pasteur de Madagascar, Antananarivo, Madagascar

⁷Faculté des Sciences, Université de Toliara, Toliara, Madagascar

⁸Direction de La Démographie et des Statistiques Sociales, Institut National de La Statistique, Antananarivo, Madagascar

⁹National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia

¹⁰National Institute for Medical Research, Dar es Salaam, Tanzania

¹¹Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique

¹²National Malaria Control Program, Ministry of Health, Luanda, Angola

¹³National Malaria Control Program, Ministry of Health, Porto-Novo, Benin

¹⁴Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Forecariah, Guinea

¹⁵Kenya Medical Research Institute (KEMRI)-Centre for Global Health Research, Kisumu, Kenya

¹⁶Infectious Diseases Research Collaboration (IDRC), Kampala, Uganda

¹⁷Malaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre (RBC), Kigali, Rwanda

¹⁸Unit of Clinical Pharmacology and Pharmacovigilance University of Kinshasa, Kinshasa, Democratic Republic of the Congo

¹⁹Department of Pharmacology and Therapeutics, University of Kinshasa, Kinshasa, Democratic Republic of the Congo

²⁰Ethiopian Public Health Institute, Arbegnoch Street, Addis Ababa, Ethiopia

²¹Mali-Tulane Tropical Medicine Research Center, Faculty of Medicine, Pharmacy, and Dentistry, University of Bamako, Bamako, Mali

²²U.S. President's Malaria Initiative, US Centers for Disease Control and Prevention, Kigali, Rwanda

²³Malaria Laboratory Research & Development Team, Malaria Branch, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA

Author contributions

Developed the study idea: VL, MP, MV, EH

Collected the data: MR, MA, HW, DI, AC, PD, AA, AB, SK, SN, AU, GK, AA, OK, NL, SS, ZZ

Analyzed the data: VL, MP, KR, LM, EH

Wrote the manuscript: VL, MP, EH

Approved the manuscript: All

Article summary:

This study suggests that: 1) patients given AL infected with parasites carrying N86 were statistically more likely to experience a recurrent infection; 2) patients given ASAQ infected with parasites carrying 86Y were statistically more likely to experience a recurrent infection.

Abstract word count: 200

Background. *Plasmodium falciparum* multidrug resistance transporter 1 (*Pfmdr1*) gene mutations are associated with altered response to artemisinin-based combination therapies (ACTs), particularly those containing the partner drugs lumefantrine and amodiaquine (i.e., artemether-lumefantrine [AL] and artesunate-amodiaquine [ASAQ]). Past studies of *Pfmdr1* single nucleotide polymorphisms (SNPs) at codons 86, 184, and 1246 have shown different responses to AL and ASAQ.

Methods. To determine whether infection with parasites carrying specific *Pfmdr1* SNPs leads to increased risk of recurrent parasitemia (recrudescent or new infection), data from 4,129 samples from 16 therapeutic efficacy studies from 13 African countries between 2013–2019 were analyzed.

Results. Patients treated with AL and infected with parasites carrying *Pfmdr1* N86 were at greater risk of treatment failure than those whose parasites carried 86Y. After treatment with ASAQ, individuals infected with parasites that carried *Pfmdr1* 86Y were more likely to experience a recurrent infection.

Conclusions. Our results support prior studies that suggested: 1) patients given AL and infected with parasites carrying N86 were more likely to experience a recurrent infection; 2) patients given ASAQ and infected with parasites carrying 86Y were more likely to experience recurrent infection. These findings suggest that ACT and *Pfmdr1* genotype may influence outcome after *P. falciparum* infection.

Keywords. malaria, *Plasmodium falciparum*, Africa, antimalarials, drug resistance

Introduction

The emergence of *Plasmodium falciparum* resistance to antimalarials poses a challenge to global malaria control efforts. World Health Organization (WHO) Guidelines for Malaria recommend the use of artemisinin-based combination therapy (ACT) to treat uncomplicated *P. falciparum* infection (1). Three ACTs used in Africa are artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP) (2). Although polymerase chain reaction (PCR)-adjusted efficacy for each ACT remains high throughout most regions (3), suboptimal ACT efficacy has been reported in Asia (4) and Africa (5–7).

Although ACT resistance has not been demonstrated with any particular *Plasmodium falciparum* multidrug resistance transporter 1 single nucleotide polymorphism (SNP) or haplotype, certain SNPs may affect response after treatment with ACTs containing lumefantrine or amodiaquine (8,9). Five unique *Pfmdr1* SNPs, with amino acid changes in codons 86, 184, 1034, 1042, and 1246, have been found in various regions of the world (10). N86, 184F, and D1246 SNPs have been found in post-treatment samples of patients who experienced a recurrent infection after AL treatment (9,11,12). Conversely, studies of SNPs in *Pfmdr1* have suggested that the 86Y and 1246Y mutations may be associated with decreased response to amodiaquine and ASAQ (9,13). Several *in vivo* studies in sub-Saharan Africa have found evidence of selection for particular *Pfmdr1* SNPs at codons 86, 184, and 1246 after treatment with AL (9,14,15). *Pfmdr1* SNPs present post-treatment in new infections are also important to understand because they may impact the post-treatment prophylactic effect of the partner drug (16). Increased copy number of *Pfmdr1* due to gene duplications has also been associated with reduced susceptibility to lumefantrine (10,17).

Sample sizes in individual therapeutic efficacy studies (TESs) are typically too small to statistically power an assessment of the association between parasite genotypes and treatment

outcomes (i.e., adequate clinical and parasitological response, recrudescence infection, and new infection). As part of the US President’s Malaria Initiative (PMI), the Centers for Disease Control and Prevention (CDC) and the US Agency for International Development provide support to countries in Africa to perform TESs, including molecular characterization of antimalarial-resistance markers, through the Partnership for Antimalarial Resistance Monitoring in Africa (PARMA) network (18). Established in 2015, this endeavor involves laboratory scientists from endemic countries coming to CDC (Atlanta, Georgia, USA) or, starting in 2022, to a partner lab in Africa to receive advanced laboratory training and perform molecular testing for antimalarial-resistance mutations (18). To examine the association between parasite genotypes and treatment outcomes, *in vivo* antimalarial efficacy and *P. falciparum* molecular marker data from samples analyzed and collected from 16 TESs conducted in 13 countries in Africa were used. Understanding this association is important for detecting changes in long-term trends of *Pfmdr1* SNP prevalence in parasite populations as indicators of changing parasite susceptibility to ACT partner drugs, lumefantrine or amodiaquine. This study had two main objectives to untangle the relationship between parasite *Pfmdr1*-genotypes and treatment outcomes: 1) To assess whether patients infected with parasites carrying specific *Pfmdr1* SNPs have increased risk of recurrent infection; 2) To investigate preferential selection of specific *Pfmdr1* SNPs by ACT type.

Methods

Selection and inclusion of data

Data for this pooled analysis were compiled from 16 individual TESs from 40 sites across 13 sub-Saharan African countries between 2013–2019 (Figure 1, Supplementary Table 1, and Supplementary Table 2). The studies were all funded by PMI.

Patients with symptomatic, parasitologically-confirmed uncomplicated *P. falciparum* symptomatic infection who presented to health facilities and met standard WHO inclusion criteria were enrolled (Supplementary Table 2) (24). Patients were administered either AL, ASAQ, or DP. After follow-up was complete, parasite genetic sequencing of *Pfmdr1* was conducted at the CDC Malaria Branch Laboratory in Atlanta, USA. This was conducted as part of a training program through PARMA (18). Eleven TES results have been published alongside molecular results, three TES efficacy results were published separately from the molecular surveillance results, and two results are contained in unpublished country reports (Benin and Zambia) (Supplementary Table 2).

Genotyping of Pfmdr1 SNPs and result calling

Patients were considered to have a recurrent infection if their sample was found by microscopy to contain asexual forms of *P. falciparum* starting on day 4 after ACT treatment until the end of the follow-up period (28, 28, and 42 days for AL, ASAQ, and DP, respectively). For study participants with recurrent infection, the recurrent infection sample and its corresponding pre-treatment sample were genotyped to determine whether the recurrent infection was a recrudescence or new infection. This was done using either seven neutral microsatellite markers (*TAI*, *Poly-α*, *PfPK2*, *TA109*, *TA2490*, *C2M34*, and *C3M69*) over six chromosomes (20,21) or using the fragment length polymorphism of genes *merozoite surface protein 1*, *merozoite surface protein 2*, and *glutamate-rich protein* (*msh1*, *msh2*, and *glurp*) (22).

Pfmdr1 codons 86, 184, 1034, 1042, and 1246 were sequenced in parasites collected from enrolled patients who experienced a recurrent infection from each TES and the SNP at each codon was recorded. Each TES sequenced *Pfmdr1* codons 86, 184, 1034, 1042, and 1246 for

typically 10% of enrolled patients who experienced an adequate clinical and parasitological response except for the Angola (2013, 2017, 2019), Democratic Republic of the Congo, and Uganda TESSs. Sanger sequencing was used to determine the genotype of the five *Pfmdr1* SNPs in pre-treatment and recurrent infections samples for each study except the 2019 Angola TES, which utilized next generation sequencing. For each SNP, samples were classified as having either a single or mixed infection (mixed genotypes) depending on whether heterozygous SNPs (double peaks representing mixed infections) were identified using the heterozygous call plug-in tool in Geneious software package (Biomatters, Inc., San Francisco, CA) with a minor allele threshold of at least 30%. Mixed infections were recorded in each study except for Tanzania. For samples with mixed infections and SNP variations at codons 86, 184 and 1246, each possible haplotype constructed from the observed SNPs was reported for *Pfmdr1*(23). *Pfmdr1* codons 1034 and 1042 were not included in the statistical analysis because the vast majority exclusively carried the wild-type SNP.

Mixed infections at the codons of interest included N and Y at codon 86 (N/Y), Y and F at codon 184 (Y/F), and D and Y at codon 1246 (D/Y). For the odds ratio analysis, mixed infections were reclassified to one SNP per codon for each treatment arm. This baseline SNP served as the exposure. For patients treated with AL, mixed infections at codon 86 were reclassified as N86; at codon 184 as 184F; and at codon 1246 as D1246. This is because previous studies have found N86, 184F, and D1246 to predominate in patients after AL treatment (9,11,12). For patients treated with ASAQ or DP, mixed infections at codon 86 were reclassified as 86Y; at codon 184 as Y184; and at codon 1246 as 1246Y. This is because previous studies have found 86Y, Y184, and 1246Y to predominate in patients after treatment with amodiaquine (11,13,24). Patients with mixed infections following treatment with DP were classified similarly

to those treated with ASAQ because piperaquine has been shown to exert selective pressure on *Pfmdr1* in the same direction as amodiaquine (25,26). We examined all recurrent infections, which included recrudescent and new infections, rather than examining solely recrudescent infections. New infections were included in this analysis because the *Pfmdr1* SNPs present post-treatment could make the parasite less susceptible to ACTs since the parasite was able to re-infect individuals soon after treatment, negating the potential post-treatment prophylactic effect of the partner drug.

Statistical analysis

All statistical analyses were conducted using R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria). Multiple sensitivity analyses using only recrudescent infections were done to assess potential bias that could occur when analyzing new infections and recrudescent infections together. The first sensitivity analysis investigated the association between those treated with AL that experienced a recrudescent infection and *Pfmdr1* codons 86 and 184. This could not be done with *Pfmdr1* codon 1246 due to small sample size. A second sensitivity analysis investigated the association between those treated with ASAQ who experienced a recrudescent infection and *Pfmdr1* codon 184. Due to the limited sample size, a sensitivity analysis for those treated with ASAQ who experienced a recrudescent and *Pfmdr1* codon 86 and 1246 could not be conducted. Similarly, a sensitivity analysis was not performed for those treated with DP since so few recrudescent infections occurred in those receiving this ACT. After this, to determine whether patients infected with parasites carrying specific *Pfmdr1* SNPs were at increased risk of recurrent (recrudescent or new) infections, the Mantel-Haenszel (MH) method was used to create forest plots. To ensure there was not significant heterogeneity among studies, a Cochran's Q test was used ($p > 0.05$). Since no statistically significant

heterogeneity was found among studies, the common effect odds ratio was reported (27). Each forest plot was created to display the common effect odds ratio by treatment arm for each country-specific study and the pooled MH odds ratio by treatment arm when the data from all studies were compiled.

The common effect odds ratio represented the odds of a specific SNP in recurrent infections (in day of failure samples from those with recrudescent or new infections) compared to the odds of that same SNP in successfully treated infections (in pre-treatment samples from those who experienced an adequate clinical or parasitological response or in pre-treatment samples who initially cleared their infection but would later acquire a new infection). For the category of samples from successfully treated patients, we included: 1) pre-treatment samples from those with an adequate clinical and parasitological response; and 2) pre-treatment samples from those who would go on to be infected with a different parasite (i.e., new infection). This is because the pre-treatment infection was successfully cleared. For the category of unsuccessfully treated patients, we included: 1) the post-treatment recrudescent samples; and 2) the post-treatment samples from those patients who were newly infected (because the patient experienced an infection while the long-acting partner drug was still circulating). Conditional logistic regression was used to investigate the relationship between all the two-codon (e.g., 86Y and Y184) and three-codon haplotype (e.g., N86, 184F, and D1246) combinations with the occurrence of recurrent infections.

In patients who experienced either a recrudescent or new infection during the follow-up period, the *Pfmdr1* SNPs of the pre-treatment and recurrent sample were compared for each of these outcomes using McNemar's test to examine selection. SNPs from pre-treatment samples were compared to their corresponding recurrent infection SNP to confirm that differences

represented selection rather than original differences in SNP frequencies among the population (9).

Results

Baseline prevalence of genetic markers associated with resistance

The baseline prevalence of SNPs was determined using all successfully sequenced pre-treatment samples. Pre-treatment SNPs at position 86 were analyzed for 2,999 samples, at position 184 for 3,050 samples, at position 1034 for 3,006 samples, at position 1042 for 3,006 samples, and at position 1246 for 3,027 samples (Table 1).

The prevalence of *Pfmdr1* SNPs varied by country (Table 1). The *Pfmdr1* N86 SNP was found in the majority of samples from every country, with the prevalence ranging from 53–100%. Samples from Ethiopia, Kenya, Mozambique, Tanzania, Uganda, and Zambia almost exclusively carried the *Pfmdr1* N86 SNP. *Pfmdr1* 184 had the most variation, with the prevalence of 184Y SNP ranging from 23–66%. Almost all samples carried parasites with the *Pfmdr1* S1034 and *Pfmdr1* N1042 wild-type alleles except for two participants from the Democratic Republic of the Congo, who carried parasites with both *Pfmdr1* 1034C and *Pfmdr1* 1042D. *Pfmdr1* D1246 SNP was found in 81–100% of the samples from most countries, with the Democratic Republic of the Congo having *Pfmdr1* D1246 in 81% of samples.

Parasite single nucleotide polymorphisms as risk factors for recurrent infection

For patients treated with AL, the odds ratio between those with wild-type N86 in recurrent infections and those with wild-type N86 in infections that were successfully cleared was 5.22 (95% CI 2.69, 10.13) (Figure 2, panel a). For those treated with ASAQ, the odds of the 86Y SNP in recurrent infections was 2.72 (95% CI 1.28, 5.79) times higher than the odds of the same SNP in infections that were successfully cleared (Figure 2, panel b). There was no

association detected between *Pfmdr1* codon 86 and recurrent infection for those treated with DP (Figure 2, panel c). Similarly, there was no association between *Pfmdr1* codons 184 or 1246 and recurrent infection in those treated with AL, ASAQ, or DP (Figures 3 and 4). When examining recrudescence infections alone (and not combined with new infections), the results of the sensitivity analysis were not statistically significant, although the odds ratios were either in the same direction as the aforementioned results or no effect was found (Supplementary Figures 1 and 2).

Country-specific odds ratios could not be generated for several countries for some treatment arms and SNPs. For example, patients who received AL in the Uganda TES only had parasites carrying the N86 SNP and none carrying the 86Y SNP following reclassification of mixed infections. Thus, the country-specific odds ratio was undefined and could not contribute to the overall, pooled MH odds ratio.

Post-treatment selection of genetic markers associated with reduced susceptibility

To examine changes in the genetic markers of parasites after drug treatment during the period of follow-up, we compared the prevalence of *Pfmdr1* SNPs in paired isolates from the initial and the recurrent parasites (Table 2). Statistically significant selection of *Pfmdr1* N86 occurred in new infections as well as recurrent infections (recrudescence infections plus new infections) after treatment with AL. There was no statistically significant selection of *Pfmdr1* SNPs at codons 184 or 1246 after AL treatment and no statistically significant selection of SNPs at *Pfmdr1* codons 86, 184, or 1246 after ASAQ or DP treatment.

Parasite haplotypes as a risk factor for recurrent infection

Recurrent infections, which included recrudescence and new infections, were pooled to assess the relationship between *Pfmdr1* haplotype and recurrent infections. Only one haplotype,

N86/184F, was found to be associated with recurrent infection. The odds of N86/184F among individuals with recurrent infection after AL treatment (post-treatment) was 6.36 (95% CI 1.39, 29.19) times higher than the odds of the same haplotype among those that successfully cleared the infection (pre-treatment). The combined effect of carrying N86/184F had a greater measure of association (OR: 6.36, 95% CI: 1.39, 29.19) than recurrent parasites only carrying N86 (OR: 5.22, 95% CI: 2.69, 10.13). There was no statistically significant selection of *Pfmdr1* haplotypes at codons 184 or 1246 after AL treatment and no statistically significant selection of haplotypes at *Pfmdr1* codons 86, 184, or 1246 after ASAQ or DP treatment.

Discussion

This pooled analysis of data from 16 efficacy studies suggests that SNPs in *Pfmdr1* codon 86 influence recurrent infection after AL and ASAQ treatment. Individuals infected with parasites that carried the *Pfmdr1* N86 SNP were statistically more likely to experience a recurrent infection after treatment with AL. This finding is consistent with a previous study which found that patients treated with AL and infected with parasites carrying the *Pfmdr1* N86 allele were at statistically greater risk of treatment failure than those whose parasites carried 86Y(9). This increased risk of recurrent infection, in addition to significant selection of *Pfmdr1* N86 by AL, could be an indicator of decreased susceptibility to the partner drug, lumefantrine.

For our haplotype analysis, patients given AL and infected with parasites carrying *Pfmdr1* N86/184F were statistically more likely to cause a new infection. This finding is similar to a study which found that after AL treatment, individuals carrying *Pfmdr1* N86/184F/D1246 were able to re-infect with lumefantrine blood concentrations 15-fold higher than those with the 86Y/Y184/1246Y haplotype (8). Another study discovered that individuals with *Pfmdr1*

N86/D1246 experienced a new infection earlier after AL treatment (9). These findings suggest that monitoring for decreasing post-treatment durations until a new infection has occurred or surveilling for the prevalence of certain post-treatment *Pfmdr1* haplotypes may also provide indications of decreased susceptibility to lumefantrine.

After treatment with ASAQ, individuals infected with parasites that carried the *Pfmdr1* 86Y SNP were statistically more likely to cause a recurrent infection, shown in this study. Like our results from those treated with AL, a high prevalence of *Pfmdr1* 86Y SNP may be an early warning signal of resistance to the partner drug, amodiaquine, but this association requires further investigation because prior studies are collectively inconclusive. An *in vitro* analysis from Southern Sudan found a significant association between failure after amodiaquine treatment and the combined presence of *Pfmdr1* 86Y and *Pfcr1* 76T but no association with *Pfmdr1* 86Y alone (28). However, an *in vivo* study from Burkina Faso found a significant association between *Pfmdr1* 86Y and treatment failures after amodiaquine treatment and another *in vivo* study from Burkina Faso showed significant selection of *Pfmdr1* 86Y after treatment with ASAQ (24,29). Additionally, a meta-analysis revealed that the risk of therapeutic failure was greater for participants who carried *Pfmdr1* 86Y and were treated with amodiaquine monotherapy (30). Our results align with the findings from Burkina Faso and the meta-analysis. Close monitoring of the prevalence of *Pfmdr1* codon 86 before and after treatment with amodiaquine monotherapy or ASAQ could be used to indicate potential partner-drug resistance to amodiaquine.

Unlike previous studies, this analysis did not find statistically significant selection of *Pfmdr1* SNPs by ASAQ (9,11,31–34). There were no significant findings between the use of DP and treatment outcomes or selection of *Pfmdr1* SNPs by DP. While this lack of association has been found before, there has also been evidence of piperaquine exerting a selective pressure on

Pfmdr1 genes similar to amodiaquine (25,26). However, there was clear evidence of significant selection of *Pfmdr1* N86 by AL in those who experienced either a recurrent infection (i.e., recrudescence or new infection) or a new infection alone in this study. This result aligns with prior studies that found selection of particular *Pfmdr1* SNPs among parasite populations after treatment with AL (8,9,12,15,17,35–40). Additionally, the significant selection of *Pfmdr1* N86 by AL is consistent with prior molecular studies that identified changes in the parasite population prevalence of *Pfmdr1* SNPs after the introduction or greater use of lumefantrine (14,15,34–37,41,42).

Although SNPs at *Pfmdr1* codon 86 were associated with recurrent infections (i.e., recrudescence or new infections), they were not associated solely with recrudescence infections in those treated with AL or ASAQ, an association shown in a prior study (9). The small number of recrudescence infections, a limitation of this study even with pooled data across 16 TES, may have prevented this analysis from finding significant results. A similar limitation was the smaller number of patients receiving ASAQ, which may have contributed to the lack of evidence of selection for *Pfmdr1* 86Y by ASAQ, a selection other studies have demonstrated [16, 23, 49–51]. Another limitation was that information on the number of *Pfmdr1* copies was not available for the majority of studies included in this analysis but has been previously found as a predictor of treatment failure after AL treatment (10,17). Additionally, most of the efficacy studies enrolled patients under 6 years old. Therefore, our data may not be applicable to adult populations. Lastly, efficacy studies are not countrywide but occur in just a few sites, which may not be representative of an entire country's parasite population. Despite its limitations, our study possessed many strengths, including the large number of samples from numerous countries that were sequenced at the same laboratory using the same methodology.

Two patients from the Democratic Republic of the Congo carried parasites bearing the *Pfmdr1* haplotype commonly found in South America, *Pfmdr1* 1034C, 1042D, and 1246Y, which has been associated with increased sensitivity to artemisinin (39,43,44). However, in our study, the participants experienced a new infection after treatment with DP. Because detailed travel histories were not available for these patients, it is unknown whether they acquired their infections locally or abroad.

Changes in the prevalence of *Pfmdr1* SNPs over multiple TESs can be a subtle sign of selection of parasite populations by AL or ASAQ. Decreasing efficacy of lumefantrine, amodiaquine, or other partner drugs leaves the artemisinin component of an ACT vulnerable to new selective pressures. Modeling demonstrates that partner drug resistant *Pfmdr1* genotypes may lead to establishment of artemisinin resistance (45). This phenomenon may already be occurring in Africa. Rwanda and Uganda, two countries reporting *K13* mutations associated with artemisinin resistance, use AL as their first-line ACT and had a predominance of the *Pfmdr1* N86 genotype in our study (7,46,47). Previous studies have shown that ASAQ and AL exert opposing selecting pressures on *Pfmdr1* 86 (9). Depending on the prevalence of *Pfmdr1* polymorphisms, the opposing selection by the partner drugs could better inform which ACT national malaria control programs could choose as a first-line therapy to delay resistance to both drugs. New strategies, such as multiple first-line therapies or dosing lumefantrine and amodiaquine together as part of a triple therapy, may overcome the negative effects of a particular *Pfmdr1* SNPs associated with decreased susceptibility to partner drugs, although that remains to be proven (48–50). Monitoring prevalence of *Pfmdr1* codons, such as N86Y, may indicate a parasite genetic background conferring reduced susceptibility to a particular antimalarial.

Acknowledgements

The authors would like to acknowledge Venkatachalam Udhayakumar for his suggestions on the manuscript and for supporting the laboratory genotyping trainings vital to this multi-country endeavor. All authors have no conflicts of interest.

Funding

Funding for this assessment was obtained from the United States President's Malaria Initiative (PMI) via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, US Agency for International Development. Staff from PMI were involved in the development of the protocol, survey tools, survey implementation, data analysis, and manuscript preparation.

Disclaimer

The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of any collaborating institute including the Centers for Disease Control and Prevention or the US Agency for International Development.

References

1. WHO Guidelines for malaria [Internet]. [cited 2023 Jun 12]. Available from: <https://www.who.int/publications-detail-redirect/guidelines-for-malaria>
2. World malaria report 2021 [Internet]. [cited 2023 Jun 12]. Available from: <https://www.who.int/publications-detail-redirect/9789240040496>
3. Shibeshi W, Alemkere G, Mulu A, Engidawork E. Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis. *BMC Infect Dis*. 2021 Apr 7;21(1):326.
4. Pluijm RW van der, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in *Plasmodium falciparum* malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. *Lancet Infect Dis*. 2019 Sep 1;19(9):952–61.
5. Gansané A, Moriarty LF, Ménard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018. *Malar J*. 2021 Jan 19;20(1):48.
6. Moriarty LF, Nkoli PM, Likwela JL, Mulopo PM, Sompwe EM, Rika JM, et al. Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance. *Am J Trop Med Hyg*. 2021 Sep 7;tpmd210214.
7. Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. *Malar J*. 2021 Dec 24;20(1):484.
8. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, et al. *Plasmodium falciparum* Drug Resistance Phenotype as Assessed by Patient Antimalarial Drug Levels and Its Association With pfmdr1 Polymorphisms. *J Infect Dis*. 2013 Mar 1;207(5):842–7.
9. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in *Plasmodium falciparum* Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for *P. falciparum* Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine. *Am J Trop Med Hyg*. 2014 Oct 1;91(4):833–43.
10. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, et al. Pfmdr1 copy number and artemisinin derivatives combination therapy failure in *falciparum* malaria in Cambodia. *Malar J*. 2009 Jan 12;8(1):11.
11. Otienoburu SD, Maïga-Ascofaré O, Schramm B, Jullien V, Jones JJ, Zolia YM, et al. Selection of *Plasmodium falciparum* pfcr1 and pfmdr1 polymorphisms after treatment with artesunate–amodiaquine fixed dose combination or artemether–lumefantrine in Liberia. *Malar J*. 2016 Sep 5;15(1):452.


- 428 12. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A, et al. The role of
429 pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int
430 Health. 2007 Jun 1;12(6):736–42.
- 431 13. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, et al. Association between
432 mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum
433 multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected
434 children in Nigeria. Am J Trop Med Hyg. 2006 Jul;75(1):155–61.
- 435 14. Baliraine FN, Rosenthal PJ. Prolonged Selection of pfmdr1 Polymorphisms After Treatment of
436 Falciparum Malaria With Artemether-Lumefantrine in Uganda. J Infect Dis. 2011 Oct
437 1;204(7):1120–4.
- 438 15. Maiga H, Grivoyannis A, Sagara I, Traore K, Traore OB, Tolo Y, et al. Selection of pfcr1 K76 and
439 pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in
440 Mali. Int J Mol Sci. 2021 Jan;22(11):6057.
- 441 16. White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malar J. 2008 Jan
442 11;7(1):9.
- 443 17. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, et al. Molecular and
444 Pharmacological Determinants of the Therapeutic Response to Artemether-Lumefantrine in
445 Multidrug-Resistant Plasmodium falciparum Malaria. Clin Infect Dis. 2006 Jun 1;42(11):1570–7.
- 446 18. Halsey ES, Venkatesan M, Plucinski MM, Talundzic E, Lucchi NW, Zhou Z, et al. Capacity
447 Development through the US President’s Malaria Initiative–Supported Antimalarial Resistance
448 Monitoring in Africa Network. Emerg Infect Dis. 2017 Dec;23(Suppl 1):S53–6.
- 449 19. World Health Organization. Methods for surveillance of antimalarial drug efficacy [Internet]. World
450 Health Organization; 2009 [cited 2022 Mar 22]. Available from:
451 <https://apps.who.int/iris/handle/10665/44048>
- 452 20. Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V. Robust Algorithm for Systematic
453 Classification of Malaria Late Treatment Failures as Recrudescence or Reinfection Using
454 Microsatellite Genotyping. Antimicrob Agents Chemother. 2015 Sep 18;59(10):6096–100.
- 455 21. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, Rosenthal PJ, et al. Validation of
456 microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J
457 Trop Med Hyg. 2006 Nov;75(5):836–42.
- 458 22. Medicines for Malaria Venture, Organization WH. Methods and techniques for clinical trials on
459 antimalarial drug efficacy: genotyping to identify parasite populations: informal consultation
460 organized by the Medicines for Malaria Venture and cosponsored by the World Health
461 Organization, 29-31 May 2007, Amsterdam, The Netherlands [Internet]. World Health
462 Organization; 2008 [cited 2022 Nov 30]. Available from:
463 <https://apps.who.int/iris/handle/10665/43824>

23. Chebore W, Zhou Z, Westercamp N, Otieno K, Shi YP, Sergeant SB, et al. Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya. *Malar J*. 2020 Aug 14;19(1):291.
24. Sondo P, Derra K, Nakanabo SD, Tarnagda Z, Kazienga A, Zampa O, et al. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. *PLOS ONE*. 2016 Mar 31;11(3):e0151565.
25. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Comparative impacts over 5 years of artemisinin-based combination therapies on *Plasmodium falciparum* polymorphisms that modulate drug sensitivity in Ugandan children. *J Infect Dis*. 2014 Aug 1;210(3):344–53.
26. Taylor SM, Juliano JJ. Artemisinin Combination Therapies and Malaria Parasite Drug Resistance: The Game Is Afoot. *J Infect Dis*. 2014 Aug 1;210(3):335–7.
27. Dettori JR, Norvell DC, Chapman JR. Fixed-Effect vs Random-Effects Models for Meta-Analysis: 3 Points to Consider. *Glob Spine J*. 2022 Sep;12(7):1624.
28. Ochong EO, van den Broek IVF, Keus K, Nzila A. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the *Plasmodium falciparum* multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. *Am J Trop Med Hyg*. 2003 Aug;69(2):184–7.
29. Tinto H, Guekoun L, Zongo I, Guiguemé RT, D'Alessandro U, Ouédraogo JB. Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso. *Trop Med Int Health TM IH*. 2008 Feb;13(2):238–40.
30. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in *falciparum* malaria. *Malar J*. 2009 May 4;8(1):89.
31. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Björkman A. Amodiaquine resistant *Plasmodium falciparum* malaria in vivo is associated with selection of pfcr 76T and pfmdr1 86Y. *Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis*. 2006 Jul;6(4):309–14.
32. Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, Safety, and Selection of Molecular Markers of Drug Resistance by Two ACTs in Mali. *Am J Trop Med Hyg*. 2008 Mar 1;78(3):455–61.
33. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, et al. Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of *Plasmodium falciparum* by chloroquine and amodiaquine. *Parasitology*. 1997 Mar;114 (Pt 3):205–11.
34. Lekana-Douki JB, Dinzouna Boutamba SD, Zatra R, Zang Edou SE, Ekomy H, Bisvigou U, et al. Increased prevalence of the *Plasmodium falciparum* Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine. *Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis*. 2011 Mar;11(2):512–7.

- 501 35. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJM, Mutabingwa TK, Sutherland CJ, et al.
502 Amodiaquine and Artemether-Lumefantrine Select Distinct Alleles of the Plasmodium falciparum
503 mdr1 Gene in Tanzanian Children Treated for Uncomplicated Malaria. Antimicrob Agents
504 Chemother [Internet]. 2007 Mar; Available from:
505 <https://journals.asm.org/doi/abs/10.1128/AAC.00875-06>
- 506 36. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, et al. In vivo selection
507 of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J
508 Infect Dis. 2005 Mar 15;191(6):1014–7.
- 509 37. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of Plasmodium
510 falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda
511 where malaria is highly endemic. Antimicrob Agents Chemother. 2006 May;50(5):1893–5.
- 512 38. Somé AF, Séré YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, et al. Selection of Known
513 Plasmodium falciparum Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and
514 Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperazine in Burkina
515 Faso. Antimicrob Agents Chemother. 2010 May;54(5):1949–54.
- 516 39. Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, et al. Increased pfmdr1 copy number
517 and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients
518 treated with artemether-lumefantrine. Antimicrob Agents Chemother. 2011 Nov;55(11):5408–11.
- 519 40. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, et al. Selection of
520 Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by
521 artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob
522 Agents Chemother. 2009 Mar;53(3):888–95.
- 523 41. Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK, et al. In vivo selection of
524 Plasmodium falciparum Pfcr1 and Pfmdr1 variants by artemether-lumefantrine and
525 dihydroartemisinin-piperazine in Burkina Faso. Antimicrob Agents Chemother. 2015
526 Jan;59(1):734–7.
- 527 42. Zhou Z, Gimnig JE, Sargent SB, Liu Y, Abong'o B, Otieno K, et al. Temporal trends in molecular
528 markers of drug resistance in Plasmodium falciparum in human blood and profiles of
529 corresponding resistant markers in mosquito oocysts in Asembo, western Kenya. Malar J. 2022 Sep
530 13;21(1):265.
- 531 43. Sidhu ABS, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and
532 enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol.
533 2005;57(4):913–26.
- 534 44. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, et al. Globally prevalent
535 PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based
536 combination therapies. Nat Commun. 2016 May 18;7(1):11553.
- 537 45. Watson OJ, Gao B, Nguyen TD, Tran TNA, Penny MA, Smith DL, et al. Pre-existing partner-drug
538 resistance to artemisinin combination therapies facilitates the emergence and spread of
539 artemisinin resistance: a consensus modelling study. Lancet Microbe. 2022 Sep 1;3(9):e701–10.

46. Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of *Plasmodium falciparum* kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. *Lancet Infect Dis*. 2021 Aug 1;21(8):1120–8.
47. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of Artemisinin-Resistant Malaria in Africa. *N Engl J Med*. 2021 Sep 23;385(13):1163–71.
48. Boni MF, White NJ, Baird JK. The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies. *PLOS Med*. 2016 Mar 29;13(3):e1001984.
49. Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HDT, Nguon C, et al. Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated *falciparum* malaria: an open-label, randomised, multicentre trial. *Lancet Infect Dis*. 2022 Jun;22(6):867–78.
50. Boni MF. Breaking the cycle of malaria treatment failure. *Front Epidemiol* [Internet]. 2022;2. Available from: <https://www.frontiersin.org/articles/10.3389/fepid.2022.1041896>

565 Tables & Figures



566 **Figure 1.** Countries and sites contributing data to this *Pfmdr1* meta-analysis.

Table 1. Baseline (pre-treatment) prevalence of *Pfmdr1* single nucleotide polymorphisms*

Marker	Angola	Benin	DRC	Ethiopia	Guinea	Kenya	Madagascar	Mali	Mozambique	Rwanda	Tanzania	Uganda	Zambia	Total
Number of samples	572	164	260	48	420	320	157	311	109	208	271	128	230	3,135
<i>Pfmdr1</i>[†] 86														
Sequenced	511	152	258	48	385	320	153	255	109	208	269	128	203	2,999
N	433 (85)	144 (89)	138 (53)	47 (99)	306 (80)	319 (99)	120 (78)	206 (81)	109 (100)	200 (95)	268 (99)	128 (100)	202 (99)	2,620 (87)
N/Y	8 (2)	1 (<1)	38 (15)	0	24 (6)	1 (<1)	4 (3)	15 (6)	0	5 (4)	0	0	0	96 (3)
Y	70 (13)	17 (10)	82 (32)	1 (<1)	55 (14)	0	29 (19)	34 (13)	0	3 (<1)	1 (<1)	0	1 (<1)	293 (10)
<i>Pfmdr1</i> 184														
Sequenced	512	162	258	48	385	320	154	293	109	208	270	128	203	3,050
Y	341 (66)	43 (27)	150 (58)	11 (23)	119 (31)	130 (41)	53 (34)	83 (28)	42 (39)	99 (47)	165 (61)	48 (37)	127 (63)	1,411 (46)
Y/F	39 (8)	27 (17)	60 (23)	2 (4)	56 (14)	77 (24)	9 (6)	34 (12)	24 (22)	20 (10)	0	37 (29)	4 (2)	389 (14)
F	132 (26)	92 (56)	48 (19)	35 (73)	210 (55)	113 (35)	92 (60)	176 (60)	43 (39)	89 (43)	105 (39)	43 (34)	72 (35)	1,250 (40)
<i>Pfmdr1</i> 1034														
Sequenced	503	150	260	47	374	320	149	307	109	207	270	126	184	3,006
S	503 (100)	150 (100)	258 (99)	47 (100)	374 (100)	320 (100)	149 (100)	307 (100)	109 (100)	207 (100)	270 (100)	126 (100)	184 (100)	3,004 (99)
S/C	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C	0	0	2 (<1)	0	0	0	0	0	0	0	0	0	0	2 (<1)
<i>Pfmdr1</i> 1042														
Sequenced	503	150	260	48	374	320	149	307	109	206	270	127	183	3,006
N	503 (100)	150 (100)	258 (99)	48 (100)	374 (100)	320 (100)	149 (100)	307 (100)	109 (100)	206 (100)	270 (100)	127 (100)	183 (100)	3,004 (99)
N/D	0	0	0	0	0	0	0	0	0	0	0	0	0	0
D	0	0	2 (<1)	0	0	0	0	0	0	0	0	0	0	2 (<1)
<i>Pfmdr1</i> 1246														
Sequenced	513	150	260	48	371	320	139	307	109	208	270	127	205	3,027
D	505 (98)	150 (100)	210 (81)	48 (100)	362 (97)	289 (89)	133 (96)	302 (98)	10 (100)	194 (93)	268 (99)	116 (91)	201 (98)	2,887 (95)
D/Y	0	0	18 (7)	0	3 (1)	(20 (7)	0	0	0	4 (2)	0	5 (4)	2 (1)	52 (2)
Y	8 (2)	0	32 (12)	0	6 (2)	11 (4)	6 (4)	5 (2)	0	10 (5)	2 (1)	6 (5)	2 (1)	88 (3)

*Values are no. (%) of successfully sequenced samples

[†]*Pfmdr1*=*Plasmodium falciparum* multidrug resistance 1 gene.

Table 2. Selection of *Pfmdr1* genotypes after treatment with artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine*

572

Marker	Genotype [†]	Recurrent infection			□	Recrudescent infection			□	New infection		
		AL	ASAQ	DP		AL	ASAQ	DP		AL	ASAQ	DP
<i>Pfmdr1</i> 86	N→Y	(11/647)	(9/99)	(22/205)	□	(1/153)	(1/27)	(2/37)	□	(10/494)	(8/72)	(20/168)
□	Y→N	(32/647)	(22/99)	(26/205)	□	(3/153)	(5/27)	(3/37)	□	(29/494)	(17/72)	(23/168)
□	No change**	(604/647)	(68/99)	(157/205)	□	(149/153)	(21/27)	(32/37)	□	(455/494)	(47/72)	(125/168)
P value	□	<0.01	0.03 (exact)	0.56	□	0.62	0.22 (exact)	1 (exact)	□	<0.01	0.11 (exact)	0.65
<i>Pfmdr1</i> 184	Y→F	(119/639)	(17/101)	(44/205)	□	(22/153)	(15/36)	(7/37)	□	(95/486)	(10/74)	(39/168)
□	F→Y	(117/639)	(16/101)	(35/205)	□	(27/153)	(2/36)	(5/37)	□	(92/486)	(15/74)	(28/168)
□	No change**	(403/639)	(68/101)	(126/205)	□	(104/153)	(19/36)	(25/37)	□	(299/486)	(49/74)	(101/168)
P value	□	0.89	1	0.31	□	0.48	0.29 (exact)	0.77 (exact)	□	0.82	0.42 (exact)	0.18
<i>Pfmdr1</i> 1246	D→Y	(9/618)	(6/105)	(16/205)	□	(2/150)	(2/27)	(2/37)	□	(7/468)	(6/78)	(14/168)
□	Y→D	(17/618)	(8/105)	(9/205)	□	(2/150)	(2/27)	(2/37)	□	(15/468)	(4/78)	(7/168)
□	No change**	(592/618)	(91/105)	(180/205)	□	(146/150)	(23/27)	(33/37)	□	(446/468)	(68/78)	(147/168)
P value	□	0.17	0.77 (exact)	0.16	□	1	1 (exact)	1 (exact)	□	0.14	0.75 (exact)	0.19

AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine

*Values in bold indicate statistically significant selection (P<0.05) using McNemar's paired test. Those marked exact were tested by using the exact distribution for sample sizes less than 100.

Pfmdr1=*Plasmodium falciparum* multidrug resistance 1 gene

†Each category includes all changes from one allele to another. For example, N→Y includes N→Y, N→N/Y, and N/Y→Y changes; Y→N includes Y→N, Y→N/Y, N/Y→N changes.

**No change in genotype from before and after treatment.

Note: recurrent infections are the combination of recrudescent and new infections




Figure 2. **a)** Forest plot of recurrent parasitemia in patients treated with AL. Odds ratio of N86 among patients with recurrent parasitemia compared to the odds ratio of N86 among patients who successfully cleared the infection. **b)** Forest plot of recurrent parasitemia in patients treated with ASAQ. Odds ratio of 86Y among patients with recurrent parasitemia compared to the odds ratio of 86Y among those who successfully cleared the infection. **c)** Forest plot of recurrent parasitemia in patients treated with DP. Odds ratio of 86Y among patients with recurrent parasitemia compared to the odds ratio of 86Y among patients who successfully cleared the infection. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; OR, odds ratio; CI, confidence interval.




Figure 3. **a)** Forest plot of recurrent parasitemia in patients treated with AL. Odds ratio of 184F among patients with recurrent parasitemia compared to the odds ratio of 184F among patients who successfully cleared the infection. **b)** Forest plot of recurrent parasitemia in patients treated with ASAQ. Odds ratio of Y184 among patients with recurrent parasitemia compared to the odds ratio of Y184 among patients who successfully cleared the infection. **c)** Forest plot of recurrent parasitemia in patients treated with DP. Odds ratio of 86Y among patients with recurrent parasitemia compared to the odds ratio of Y184 among patients who successfully cleared the infection. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; OR, odds ratio; CI, confidence interval.




Figure 4. **a)** Forest plot of recurrent parasitemia in patients treated with AL. Odds ratio of D1246 among patients with recurrent parasitemia compared to the odds ratio of D1246 among patients who successfully cleared the infection. **b)** Forest plot of recurrent parasitemia in patients treated with ASAQ. Odds ratio of 1246Y among patient with recurrent parasitemia compared to the odds ratio of 1246Y among patients who successfully cleared the infection. **c)** Forest plot of recurrent parasitemia in patients treated with DP. Odds ratio of 1246Y among patients with recurrent parasitemia compared to the odds ratio of 1246Y among patients who successfully cleared the infection. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; OR, odds ratio; CI, confidence interval.

Supplementary Table 1. Uncorrected and PCR–corrected efficacies for therapeutic efficacy study sites

Country	Site	Year(s) of study	AL uncorrected efficacy (%, 95% CI)	AL PCR- corrected efficacy (%, 95% CI)	ASAQ uncorrected efficacy (%, 95% CI)	ASAQ PCR- corrected efficacy (%, 95% CI)	DP uncorrected efficacy (%, 95% CI)	DP PCR- corrected efficacy (%, 95% CI)
Angola	Uige	2013	92 [84–97]	97 [91–100]	–	–	100 ^a	100 ^a
	Zaire		77 [69–87]	88 [79–95]*	–	–	99 [96–100]	100 ^a
	Benguela	2015	90 [83–96]	96 [89–99]	90 [84–97]	99 [95–100]	100	100
	Lunda Sul		–	–	100	100	96 [91–100]	99 [96–100]
	Zaire		76 [68–85]	88 [81–95]*			100 [100–100]	100
	Benguela	2017	–	–	99 [97–100]	100 [97–100]	101 [100–100]	101 [100–100]
	Lunda Sul		90 [82–95]	96 [90–99]	–	–		
	Zaire		93 [88–98]	96 [91–100]	82 [75–90]	93 [88–99]		
	Benguela	2019	90 [85–96]	98 [96–100]	100 ^a	100 ^a	–	–
	Lunda Sul		85 [79–93]	88 [81–95]*	100 ^a	100 ^a	–	–
	Zaire		84 [77–92]	92 [87–98]	85 [78–92]	96 [91–100]	–	–
Benin	Klouékanmey	2017	99 [94–100]	100 [97–100]	–	–	–	–
	Djougou		91 [83–98]	98 [94–100]	–	–	–	–
	Kabondo		88 [82–95]	98 [95–100]	100 [100–100]	100 [100–100]	91 [85–98]	100 [99–100]
	Kapolowe	2017– 2018	76 [68–85]	94 [89–99]	100 [100–100]	100 [100–100]	64 [56–75]	93 [87–99]
	Kimpese		85 [78–94]	96 [92–100]	93 [88, 99]	99 [98–100]	90 [84–97]	100 [99–100]
	Mikalayi		63 [55–74]	86 [79, 93]*	77 [69–86]	96 [91–99]	56 [47–67]	84 [75–93]*
	Rutshuru		80 [72–89]	96 [92–100]	73 [64–83]	91 [85–98]	59 [50–70]	95 [90–100]
Ethiopia	Arbaminch	2017	100 ^a	100 ^a	–	–	100 ^a	100 ^a
	Pawe		98 [91–99]	98 [91–99]	–	–	100 ^a	100 ^a
Guinea	Labé	2016	94 [90–99]	99 [97–100]	97 [94–100]	99 [97–100]	–	–
	Maferinyah		92 [87–98]	100 ^a	95 [91–99]	100 ^a	–	–
Kenya	Siaya	2016– 2017	68 [61–76]	91 [86–96]	–	–	77 [70–84]	94 [89–98]
Madagascar	Ankazomborona	2018	99 [97–100]	100 [99–100]	100 [100–100]	100 [100–100]	–	–
	Matanga		83 [76–92]	95 [91–100]	95 [91–100]	98 [95–100]	–	–

Mali	Sélingué	2015– 2016	84 [79–89]	92 [88–97]	93 [90–97]	97 [95–99]	–	–
Mozambique	Massinga	2018	73 [62–82]	95 [87–99]	99 [94–100]	100 [96–100]	–	–
	Moatize		98 [91–100]	100 [95–100]	–	–	–	–
	Montepuez		96 [90–99]	100 [96–100]	100 [96–100]	100 [96–100]	–	–
	Mopeia		76 [66–85]	96 [88–99]	98 [92–100]	99 [94–100]	–	–
Rwanda	Bugarama	2018	84 [75–91]	97 [91–100]	–	–	–	–
	Masaka		96 [86–100]	97 [88–100]	–	–	–	–
	Rukara		76 [65–84]	94 [85–98]	–	–	–	–
	Kibaha		86 [76–92]	99 [93–100]	–	–	–	–
Tanzania	Mkuzi	2018	65 [54–75]	97 [88–100]	–	–	–	–
	Mlimba		86 [77–93]	100 [94–100]	–	–	–	–
	Ujiji		74 [63–83]	99 [92–100]	–	–	–	–
Uganda	Kwania	2018– 2019	71 [61–80]	94 [90–99]	–	–	87 [81–94]	98 [95–100]
	Arua		61 [50–70]	92 [86–98]	–	–	79 [71–88]	94 [90–99]
	Busia		41 [32–51]	87 [67–90]*	–	–	74 [65–83]	92 [87–98]
Zambia [†]	Gwembe Katete Mansa	2016	86 [77–93]	100 [95–100]	98 [92–100]	100 [96–100]	87 [78–93]	100 [95–100]

*PCR–corrected efficacy less than WHO suggested 90% threshold

Hyphens indicate a drug was not used in the study


a=Confidence intervals are undefined

[†]Uncorrected and PCR-corrected efficacies were calculated from Gwembe, Katete, and Mansa samples pooled together
AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; CI, confidence interval.

Supplementary Table 2. Summary of antimalarial therapeutic efficacy studies, thirteen countries in Africa, 2013–2017


Country	Sites	ACT(s) studied*	Study year(s)	Patient age	Number of samples	Number of patients who completed study	Genotyping method	Publication
Angola	Uige, Zaire	AL, DP	2013	6 mo–9 y	50	320	Microsatellites	(1)
	Benguela, Lunda Sul, Zaire	AL, ASAQ, DP	2015	6 mo–12 y	467	467	Microsatellites	(2,3)
	Benguela, Lunda Sul, Zaire	AL, ASAQ, DP	2017	6 mo–12 y	76	540	Microsatellites	(4)
	Benguela, Lunda Sul, Zaire	AL, ASAQ	2019	6 mo–12 y	106	579	Microsatellites	(5)
Benin	Klouékanmey, Djougou	AL	2017	6 mo–59 mo	175	235	Microsatellites	Country report
DRC	Kabondo, Kapolowe, Kimpese, Mikalayi, Rutshuru	AL, ASAQ, DP	2017–2018	6 mo–59 mo	520	1,271	Microsatellites	(6)
Ethiopia	Arba Minch, Pawe	AL, DP	2017	>6 mo	50	170	Microsatellites	(7)
Guinea	Labé, Maferinyah	AL, ASAQ	2016	6 mo–59 mo	443	413	Microsatellites	(8)
Kenya	Siaya	AL, DP	2016–2017	6 mo–59 mo	415	270	<i>msp1</i> , <i>msp2</i> , <i>glurp</i>	(9, 10)
Madagascar	Ankazomborona, Antensenavolo, Kianjavato, Matanga, Vohitromby	AL, ASAQ	2018	6 mo–14 y	179	335	Microsatellites	(11)
Mali	Sélingué	AL, ASAQ	2015–2016	6 mo–59 mo	386	434	<i>msp1</i> , <i>msp2</i> , <i>glurp</i>	(12)
Mozambique	Massinga, Moatize, Montepuez Mopeia	AL, ASAQ	2018	6 mo–59 mo	158	641	Microsatellites	(13, 14)
Rwanda	Bugarama, Masaka, Rukara	AL	2018	6 mo–59 mo	243	224	Microsatellites	(15)
Tanzania	Kibaha, Mkuzi, Mlimba, Ujiji	AL	2016	6 mo–10 y	339	335	Microsatellites	(16)
Uganda	Aduku, Arua, Masafu	AL, DP	2018–2019	6 mo–10 y	256	590	Microsatellites	(17)
Zambia	Gwembe, Katete, Mansa	AL, ASAQ, DP	2016	>6 mo	266	291	Microsatellites	Country report

*ACTs, artemisinin-based combination therapies; AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; *msp1*, merozoite surface protein-1; *msp2*, merozoite surface protein-2; *glurp*, glutamate-rich protein; DRC, Democratic Republic of the Congo




Supplementary Figure 1. Forest plot of recrudescence infection in patients treated with AL. Odds ratio of N86 among patients with recrudescence infection compared to the odds ratio of N86 among patients who successfully cleared the infection. OR, odds ratio; CI, confidence interval.

a)



b)



Supplementary Figure 2. a) Forest plot of recrudescence infection in patients treated with AL. Odds ratio of 184F among patients with recrudescence infection compared to the odds ratio of 184F among patients who successfully cleared the infection. **b)** Forest plot of recrudescence infection in patients treated with ASAQ. Odds ratio of Y184 among patients with recrudescence infection compared to the odds ratio of Y184 among patients who successfully cleared the infection. OR, odds ratio; CI, confidence interval.